ECC4703 + semaglutideOral tablet · Daily tablet + weekly injection
Phase 2U.S. MIST Phase 2a; active, not recruiting; results pending
← Therapy pipeline
Investigational · Obesity development
ECC4703
ECC-4703 · MIST · EC0011 · Eccogene
Oral THR-β agonist studied as an adjunct to semaglutide for obesity, including effects on weight, liver fat and body composition.
THR-β
Other study areas
Body compositionLiver disease (MASLD / MASH)
Selected program areas, not approvals. See the full profile for individual trials.Obesity stagePhase 2
Phase 1Phase 2Phase 3Regulatory review
Updated as of November 2026SponsorEccogene
TargetsTHR-β
RouteOral tablet
DevelopmentObesity-specific
Results availability
No numerical results shown
MIST obesity results are pending. This liver-targeting thyroid hormone receptor beta (THR-β) agonist is intended to complement semaglutide through a different metabolic pathway; benefit for human weight or lean-mass preservation has not yet been established.
Safety context
No MIST combination safety results were found in the reviewed sources. Safety and tolerability, liver tests, thyroid function and other clinical measures require trial evaluation; early studies or animal findings do not establish safety in obesity treatment.
Mechanism at a glance
GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targetsTargeted
Body-composition and other targets appear alongside hormone pathways in this overview.
Explore the hormone anatomy ↗Obesity stage by formulation
Milestone → next
Latest: MIST enrolled 151 participants at U.S. sites. The registry remains active, not recruiting; its October 15, 2026 completion date is an estimate, not confirmation that the study has finished.
Next: MIST results and a subsequent development decision; no human obesity efficacy results were located in the sources reviewed.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
MIST · ECC4703 added to semaglutide
Weight managementStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
U.S. randomized, blinded Phase 2a study in 151 adults with BMI ≥30 and without diabetes. Oral ECC4703 daily plus weekly injectable semaglutide versus oral placebo plus semaglutide. Registry primary measures include body-weight change, ≥5% weight-loss response, and MRI-PDFF liver-fat outcomes in the imaging subgroup, comparing week 9 baseline with week 20. Sponsor describes 12 weeks of adjunct treatment within the study schedule. Dose amounts are not disclosed in the reviewed sources. Last registry update June 25, 2026; estimated completion October 15 is not an actual completion report.